- Home
- SNDX vs SBH Comparison
SNDX vs SBH Comparison
Compare SNDX & SBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- SBH
- Stock Information
- Founded
- SNDX 2005
- SBH 1964
- Country
- SNDX United States
- SBH United States
- Employees
- SNDX N/A
- SBH N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- SBH Other Specialty Stores
- Sector
- SNDX Health Care
- SBH Consumer Discretionary
- Exchange
- SNDX Nasdaq
- SBH Nasdaq
- Market Cap
- SNDX 1.3B
- SBH 1.4B
- IPO Year
- SNDX 2016
- SBH 2006
- Fundamental
- Price
- SNDX $16.42
- SBH $15.80
- Analyst Decision
- SNDX Strong Buy
- SBH Buy
- Analyst Count
- SNDX 10
- SBH 5
- Target Price
- SNDX $38.40
- SBH $13.88
- AVG Volume (30 Days)
- SNDX 1.9M
- SBH 2.2M
- Earning Date
- SNDX 11-04-2025
- SBH 11-13-2025
- Dividend Yield
- SNDX N/A
- SBH N/A
- EPS Growth
- SNDX N/A
- SBH 35.04
- EPS
- SNDX N/A
- SBH 1.85
- Revenue
- SNDX $77,933,000.00
- SBH $3,689,376,000.00
- Revenue This Year
- SNDX $642.36
- SBH $0.16
- Revenue Next Year
- SNDX $108.58
- SBH $1.32
- P/E Ratio
- SNDX N/A
- SBH $8.55
- Revenue Growth
- SNDX 2126.66
- SBH N/A
- 52 Week Low
- SNDX $8.58
- SBH $7.54
- 52 Week High
- SNDX $22.50
- SBH $16.82
- Technical
- Relative Strength Index (RSI)
- SNDX 61.98
- SBH 57.45
- Support Level
- SNDX $14.93
- SBH $16.07
- Resistance Level
- SNDX $15.99
- SBH $16.82
- Average True Range (ATR)
- SNDX 0.70
- SBH 0.52
- MACD
- SNDX 0.04
- SBH -0.07
- Stochastic Oscillator
- SNDX 83.26
- SBH 44.75
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About SBH Sally Beauty Holdings Inc. (Name to be changed from Sally Holdings Inc.)
Sally Beauty Holdings Inc is a professional beauty-products retailer based in the United States. Sally Beauty operates throughout the United States, Puerto Rico, the United Kingdom, Belgium, Canada, Chile, Mexico, Peru, France, Ireland, Spain, Germany, and the Netherlands. The company operates through two business segments: Sally Beauty Supply and Beauty Systems Group. Product offerings include hair color and care, hair dryers and hair-styling appliances, nail care, skin care, and others.